treatment

“Green light” to Lilly’s monoclonal antibody to migraine

INDUSTRY, MEDICAL COMMUNITY, News, PATIENTS, PATIENTS ASSOCIATIONS / By

Eli Lilly announces that the European Commission (EC) has approved the commercialization of galcanezumab ( Emgality ) as a prophylactic treatment of migraine in adults suffering from at least four days of migraine per month . Galcanezumab is a humanized monoclonal antibody that binds to the peptide related to the calcite gene (CGRP, for its acronym in English) associated with episodes […]

“Green light” to Lilly’s monoclonal antibody to migraine Read More »

Women and Migrain

MEDICAL COMMUNITY, News, PATIENTS / By

Women and Migraine Women and migraine: Estrogen may explain why women suffer more often migraines Spanish researchers have discovered that the role of this sex hormone around the trigeminal nerve could be key in migraine episodes, which could explain why woman suffer from them more often.  Sex hormones could play a key role in the

Women and Migrain Read More »

New Aimovig Medication Approved

INDUSTRY, News, PATIENTS / By

Novartis marks a new era for migraine patients with the EU approval of Aimovig®, a first-of-its- kind treatment specifically designed for migraine prevention Jul 30, 2018 New Aimovig Medication Approved Novartis announced today that the European Commission (EC) approved Aimovig® (erenumab) for the prevention of migraine in adults experiencing four or more migraine days per month.

New Aimovig Medication Approved Read More »

Why are migraine patients skipping effective behavioral treatments?

MEDICAL COMMUNITY, News, PATIENTS / By

Effective behavioral treatments for migraine are being eschewed by a significant number of sufferers, according to a new study led by headache researchers at NYU School of Medicine. Researchers found that about half of migraine patients who were referred by a headache center for specific behavioral treatment did not follow through with therapy. This occurred

Why are migraine patients skipping effective behavioral treatments? Read More »

Novartis’ Migraine prevention therapy is closer to being approved

INDUSTRY, News / By

Friday, June 1, 2018, at 15:45 Novartis has announced that the European Medicines Agency (EMA) Committee on Human Use Medicines (CHMP) has recommended Aimovig (erenumab) approval to prevent migraine in adults suffering at least 4 days of migraine per month. The World Health Organization (WHO) has mentioned migraine as one of the top ten causes

Novartis’ Migraine prevention therapy is closer to being approved Read More »

logo-emha-footer
MENU
LASTEST NEWS
ALL NEWS
SOCIAL
Facebook Instagram Twitter Youtube
Scroll to Top

FOR YOU

Working together we can achieve a better future for all patients living with migraine.

Facebook Instagram Twitter Youtube
Search
Close this search box.
Facebook Instagram Twitter Youtube